Yaming Li

Prof. Yaming Li

Huadong Hospital, Fudan University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2015 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
WWWenbin Wan
Wenbin Wan
LCLan Cao
Lan Cao
LLLumei Liu
Lumei Liu
CZChunyan Zhang
Chunyan Zhang
BKBill Kalionis
Bill Kalionis
SXShijin Xia
Shijin Xia

1 September 2014 in Neurochemistry International
Verified
Journal Article
Closed access
LLLumei Liu
Lumei Liu
WWWenbin Wan
Wenbin Wan
SXShijin Xia
Shijin Xia
BKBill Kalionis
Bill Kalionis
YLYaming Li
Yaming Li

1 August 2016 in Experimental Gerontology
Verified
Journal Article
Closed access
WWWenbin Wan
Wenbin Wan
CZChunyan Zhang
Chunyan Zhang
MDMark Danielsen
Mark Danielsen
QLQianlei Li
Qianlei Li
WCWenjing Chen
Wenjing Chen
YLYaming Li
Yaming Li

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
WWWenbin Wan
Wenbin Wan
SXShijin Xia
Shijin Xia
BKBill Kalionis
Bill Kalionis
LLLumei Liu
Lumei Liu
YLYaming Li
Yaming Li
Accumulating evidence supports a key role for Wnt signaling in the development of the central nervous system (CNS) during embryonic development and in the regulation of the structure and function of the adult brain. Alzheimer’s disease (AD) is the most common form of senile dementia, which is characterized byβ-amyloid (Aβ) deposition in specific brain regions. However, the molecular mechanism underlying AD pathology remains elusive. Dysfunctional Wnt signaling is associated with several diseases such as epilepsy, cancer, metabolic disease, and AD. Increasing evidence suggests that downregulation of Wnt signaling, induced by Aβ, is associated with disease progression of AD. More importantly, persistent activation of Wnt signaling through Wnt ligands, or inhibition of negative regulators of Wnt signaling, such as Dickkopf-1 (DKK-1) and glycogen synthase kinase-3β(GSK-3β) that are hyperactive in the disease state, is able to protect against Aβtoxicity and ameliorate cognitive performance in AD. Together, these data suggest that Wnt signaling might be a potential therapeutic target of AD. Here, we review recent studies related to the progression of AD where Wnt signaling might be relevant and participate in the development of the disease. Then, we focus on the potential relevance of manipulating the Wnt signaling pathway for the treatment of AD.

26 November 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WWWen-Bin Wan
Wen-Bin Wan
LCLan Cao
Lan Cao
LLLu-Mei Liu
Lu-Mei Liu
BKBill Kalionis
Bill Kalionis
CCChuan Chen
Chuan Chen
SXShijin Xia
Shijin Xia
Alzheimer’s disease (AD) is the most common form of senile dementia which is characterized by abnormal amyloid beta (Aβ) accumulation and deposition in brain parenchyma and cerebral capillaries, and leads to blood-brain barrier (BBB) disruption. Despite great progress in understanding the etiology of AD, the underlying pathogenic mechanism of BBB damage is still unclear, and no effective treatment has been devised. The standard Ginkgo biloba extract EGb761 has been widely used as a potential cognitive enhancer for the treatment of AD. However, the cellular mechanism underlying the effect remain to be clarified. In this study, we employed an immortalized endothelial cell line (bEnd.3) and incubation of Aβ1–42 oligomer, to mimic a monolayer BBB model under conditions found in the AD brain. We investigated the effect of EGb761 on BBB and found that Aβ1–42 oligomer-induced cell injury, apoptosis, and generation of intracellular reactive oxygen species (ROS), were attenuated by treatment with EGb761. Moreover, treatment of the cells with EGb761 decreased BBB permeability and increased tight junction scaffold protein levels including ZO-1, Claudin-5 and Occludin. We also found that the Aβ1–42 oligomer-induced upregulation of the receptor for advanced glycation end-products (RAGE), which mediates Aβ cytotoxicity and plays an essential role in AD progression, was significantly decreased by treatment with EGb761. To our knowledge, we provide the first direct in vitro evidence of an effect of EGb761 on the brain endothelium exposed to Aβ1–42 oligomer, and on the expression of tight junction (TJ) scaffold proteins and RAGE. Our results provide a new insight into a possible mechanism of action of EGb761. This study provides a rational basis for the therapeutic application of EGb761 in the treatment of AD.

14 August 2021 in Neural Plasticity
Verified
Journal Article
Open access
PDF file
ZLZhongkuan Lyu
Zhongkuan Lyu
YCYuanjin Chan
Yuanjin Chan
QLQiyue Li
Qiyue Li
QZQiang Zhang
Qiang Zhang
KLKaili Liu
Kaili Liu
ZYZhonghai Yu
Zhonghai Yu
Neuroinflammation-related amyloid-beta peptide (Aβ) accumulation after cerebral ischemia/reperfusion (I/R) accounts for cerebral I/R injuries and poststroke dementia. Recently, pyroptosis, a proinflammatory cell death, has been identified as a crucial pathological link of cerebral I/R injuries. However, whether pyroptosis acts as a trigger of Aβ accumulation after cerebral I/R has not yet been demonstrated. Blood-brain barrier (BBB) and glymphatic system mediated by aquaporin-4 (AQP-4) on astrocytic endfeet are important pathways for the clearance of Aβ in the brain, and pyroptosis especially occurring in astrocytes after cerebral I/R potentially damages BBB integrity and glymphatic function and thus influences Aβ clearance and brain homeostasis. In present study, the method of middle cerebral artery occlusion/reperfusion (MCAO/R) was used for building models of focal cerebral I/R injuries in rats. Then, we used lipopolysaccharide and glycine as the agonist and inhibitor of pyroptosis, respectively, Western blotting for detections of pyroptosis, AQP-4, and Aβ1-42 oligomers, laser confocal microscopy for observations of pyroptosis and Aβ locations, and immunohistochemical stainings of SMI 71 (a specific marker for BBB integrity)/AQP-4 and Nissl staining for evaluating, respectively, BBB-glymphatic system and neuronal damage. The results showed that pyroptosis obviously promoted the loss of BBB integrity and AQP-4 polarization, brain edema, Aβ accumulation, and the formation of Aβ1-42 oligomers and thus increased neuronal damage after cerebral I/R. However, glycine could inhibit cerebral I/R-induced pyroptosis by alleviating cytomembrane damage and downregulating expression levels of cleaved caspase-11/1, N-terminal gasdermin D, NLRP3 (nucleotide-binding domain, leucine-rich repeat containing protein 3), interleukin-6 (IL-6) and IL-1β and markedly abate above pathological changes. Our study revealed that pyroptosis is a considerable factor causing toxic Aβ accumulation, dysfunctional BBB-glymphatic system, and neurological deficits after cerebral I/R, suggesting that targeting pyroptosis is a potential strategy for the prevention of ischemic stroke sequelae including dementia.